The companies added that the OS benefit was seen in all pre-specified patient subgroups, including cisplatin eligible and ineligible cohorts, and the safety profile of the combination was consistent ...

Roger Dansey, M.D., chief oncology officer, Pfizer, said: “Patients with bladder cancer can face a poor prognosis, particularly in the advanced stages, and until recently had few available treatment ...

Pfizer (PFE) and Astellas Pharma announced ... The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups. Enfortumab vedotin plus ...

On Monday, Pfizer Inc. (NYSE:PFE ... The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups. Enfortumab vedotin plus pembrolizumab ...

The study enrolled 22 patients who were unable to be treated with cisplatin, and showed that ... and Merck KGaA/Pfizer's Bavencio (avelumab) have already shown activity in the neoadjuvant MIBC ...

Adding the results of EV-302 to the label makes it an option for cisplatin-eligible patients as well – a much larger population. The peak sales figure is for the drug overall, with Pfizer ...